We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Agilent Awards Influential Clinical Genomics Researcher

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agilent Awards Influential Clinical Genomics Researcher"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Agilent Technologies Inc. announced that Peter Robinson, M.D., MSC, has received an Agilent Thought Leader Award in recognition of his contributions to clinical genomics and computational biology.

The award includes funding that will enable Dr. Robinson to extend his research efforts to identify non-coding regions of the genome involved in gene regulation and disease. Of particular interest are those regions located far away from the genes they regulate or ‘enhancer’ regions that typically escape exome sequencing analysis.

“Dr. Robinson focuses on the identification of enhancer mutations involved in various human diseases and conditions. His research will increase our understanding of the disease relevance of regulatory regions in the genome, as well as demonstrate the utility of targeted sequence capture for such studies," said Herman Verrelst, Agilent vice president and general manager, Genomics and Clinical Applications Division, and the executive sponsor of this award. "We are pleased to support Dr. Robinson’s work in this important area,” added Verrelst.

“I’m very grateful for this award as it will allow us to examine the influence of DNA variation and dysregulation of gene regulation in immune cells, as well as cohorts of patients with diseases of the immune system, in order to address the hypothesis that alterations of enhancer-promoter looping interactions may underlie some forms of immunological disease,” said Dr. Robinson. “The work will involve genomics investigations in which relevant regulatory regions of the genome are enriched and subjected to next-generation sequencing. We will also develop bioinformatics pipelines and algorithms in order to process and analyse the resulting data, as well as software methods for biological and medical interpretation, with the goal of establishing robust methods for the use of this kind of genomics to investigate the disease relevance of non-coding regions of our genome,” he added.


Story from Agilent Technologies. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.